AUROBINDO PHARMA LTD

Aurobindo Pharma Limited reported a 16% year-on-year increase in consolidated revenues for Q1 FY27, reaching Rs. 9,150 crores, driven by strong performance across its business segments. The formulation business grew by 17% to Rs. 8,101 crores, contributing 89% of total revenues. The U.S. market saw an 8.1% revenue increase to Rs. 3,770 crores, with 10 new product launches. The company completed the acquisition of Lannett, enhancing its U.S. platform and expanding its product offerings. Operating EBITDA stood at Rs. 1,924 crores, with a margin of 21%. Management reiterated its guidance for FY27, aiming for double-digit revenue growth and EBITDA margins above 21%. The company emphasized its focus on high-value businesses and improving capital productivity, while also highlighting ongoing developments in its biosimilars and biologics segments. The earnings call included a Q&A session addressing various operational aspects and market strategies.

Management highlighted strong revenue growth and strategic acquisitions, indicating a positive performance.